Xintela AB (publ) (STO:XINT)
Sweden · Delayed Price · Currency is SEK 0.1670
+0.0095 (6.03%)
Sep 22, 2026, 1:34 PM CET
Xintela AB Earnings Call Transcripts
Fiscal Year 2025
-
XSTEM demonstrated safety and sustained efficacy in osteoarthritis patients, with the highest dose halting cartilage degradation and improving bone structure over two years. The platform's unique MSC selection and in-house GMP facility support expansion into new indications and commercial partnerships.